Neoplasia — MCQs
On this page
Where are the BRCA-1 and BRCA-2 genes located, respectively?
Which of the following is associated with a moderately increased risk for invasive breast carcinoma?
A study of women with breast carcinoma is done to determine the presence and amount of estrogen receptor (ER) and progesterone receptor (PR) in the carcinoma cells. Large amounts of ER and PR are found in the carcinoma cells of some patients, while these receptors are not present in the cells of other patients. Patients with positivity for ER and PR are likely to exhibit which of the following traits?
"Basal-like" carcinoma of breast can be identified as:
Thymoma can be associated with all of the following conditions, EXCEPT:
Which of the following is NOT a malignant feature?
Which of the following statements about chromothrypsis is NOT true?
A woman who is heterozygous for glucose-6-phosphate dehydrogenase (G6PD), a polymorphic enzyme transcribed from the X chromosome, develops chronic myeloid leukemia. Restriction fragment length polymorphism (RFLP) studies on the tumor cells for G6PD reveal that only a single form of the enzyme is transcribed. This finding supports which of the following features of neoplasia?
What is the commonest site for the spread of cancers?
What is the most specific immunohistochemical marker for melanoma cells?
Neoplasia Indian Medical PG Practice Questions and MCQs
Question 141: Where are the BRCA-1 and BRCA-2 genes located, respectively?
- A. Chromosome 17 and Chromosome 22
- B. Chromosome 17 and Chromosome 13 (Correct Answer)
- C. Chromosome 22 and Chromosome 17
- D. Chromosome 13 and Chromosome 17
Explanation: **Explanation:** The correct answer is **Option B (Chromosome 17 and Chromosome 13)**. **BRCA1 and BRCA2** are tumor suppressor genes that encode proteins involved in the repair of double-stranded DNA breaks via homologous recombination [3]. Mutations in these genes significantly increase the risk of hereditary breast and ovarian cancer (HBOC) syndromes [1]. 1. **BRCA1** is located on the long arm (q) of **Chromosome 17** (specifically 17q21). A helpful mnemonic is that BRCA**1** is on Chromosome **17** (both have a '1' and a '7'). 2. **BRCA2** is located on the long arm (q) of **Chromosome 13** (specifically 13q12.3). **Analysis of Incorrect Options:** * **Option A & C:** Chromosome 22 is associated with the *NF2* gene (Merlin protein). While Chromosome 17 is correct for BRCA1 [4], it is not the location for BRCA2. * **Option D:** This reverses the order. In medical entrance exams, "respectively" indicates that the first gene (BRCA1) must match the first chromosome (17) and the second gene (BRCA2) must match the second chromosome (13). **High-Yield Clinical Pearls for NEET-PG:** * **Inheritance:** Both follow an **Autosomal Dominant** pattern with variable penetrance [3]. * **BRCA1 Associations:** Higher risk of medullary carcinoma of the breast, serous ovarian carcinoma, and fallopian tube cancer [1]. * **BRCA2 Associations:** Strongly associated with **male breast cancer**, prostate cancer, and pancreatic cancer [2]. * **Mechanism:** Loss of function leads to genomic instability. Cells with these mutations are highly sensitive to **PARP inhibitors** (e.g., Olaparib) due to "synthetic lethality." **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1058-1059. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Pancreas, pp. 898-899. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 298-300. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1059-1060.
Question 142: Which of the following is associated with a moderately increased risk for invasive breast carcinoma?
- A. Sclerosing adenoma
- B. Apocrine metaplasia
- C. Duct ectasia
- D. Atypical ductal hyperplasia (Correct Answer)
Explanation: **Explanation:** The risk of developing invasive breast carcinoma is categorized based on the histological findings of benign breast lesions [1][2]. This classification is crucial for NEET-PG as it dictates clinical management. **Correct Answer: D. Atypical ductal hyperplasia (ADH)** ADH is characterized by a proliferation of monomorphic cells that partially fill the ductal space [1]. According to the Dupont and Page criteria, it is classified as **Proliferative Disease with Atypia**. This category carries a **moderately increased risk (4 to 5 times)** of developing invasive carcinoma in either breast [1]. If a patient also has a first-degree family history of breast cancer, the risk can increase up to 10-fold. **Analysis of Incorrect Options:** * **A. Sclerosing adenoma:** This is a **Proliferative Disease without Atypia**. It carries only a **mildly increased risk (1.5 to 2 times)** [1]. Other examples in this category include radial scars and complex sclerosing lesions. * **B. Apocrine metaplasia:** This is a **Non-proliferative change** (often part of fibrocystic changes) [2]. It carries **no increased risk (1.0x)** of malignancy. * **C. Duct ectasia:** This is an inflammatory condition involving the dilation of large ducts [2]. It is a **Non-proliferative lesion** and carries **no increased risk**. **High-Yield Clinical Pearls for NEET-PG:** 1. **No Risk (1x):** Cyst, Apocrine metaplasia, Mild hyperplasia, Duct ectasia, Fibroadenoma (without complex features). 2. **Slight Risk (1.5–2x):** Moderate/florid hyperplasia (without atypia), Sclerosing adenosis, Papilloma, Radial scar. 3. **Moderate Risk (4–5x):** Atypical Ductal Hyperplasia (ADH) and Atypical Lobular Hyperplasia (ALH). 4. **High Risk (8–10x):** Ductal Carcinoma in Situ (DCIS) and Lobular Carcinoma in Situ (LCIS). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1052-1056. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, p. 1052.
Question 143: A study of women with breast carcinoma is done to determine the presence and amount of estrogen receptor (ER) and progesterone receptor (PR) in the carcinoma cells. Large amounts of ER and PR are found in the carcinoma cells of some patients, while these receptors are not present in the cells of other patients. Patients with positivity for ER and PR are likely to exhibit which of the following traits?
- A. Greater immunogenicity
- B. Greater likelihood of metastases
- C. Greater risk of familial breast cancer
- D. Higher response to therapy (Correct Answer)
Explanation: The presence of **Estrogen Receptor (ER)** and **Progesterone Receptor (PR)** in breast carcinoma cells is a critical prognostic and predictive factor [1]. These receptors are nuclear transcription factors that, when present, indicate that the tumor cells still retain some functional characteristics of normal mammary epithelium [1]. **1. Why the Correct Answer is Right:** The presence of ER and PR indicates that the tumor growth is dependent on hormonal stimulation [1]. This makes the tumor susceptible to **hormonal (endocrine) therapy**, such as Tamoxifen (SERM) or Aromatase Inhibitors. Patients who are ER/PR positive have a significantly **higher response to therapy** and generally carry a better prognosis compared to "triple-negative" patients [1]. **2. Why the Incorrect Options are Wrong:** * **A. Greater immunogenicity:** Immunogenicity is typically associated with high mutational burdens or viral antigens (e.g., HPV in cervical cancer), not hormone receptor status. * **B. Greater likelihood of metastases:** ER/PR positivity is actually associated with a *lower* histological grade and a less aggressive clinical course compared to receptor-negative tumors (like HER2-amplified or basal-like subtypes) [2]. * **C. Greater risk of familial breast cancer:** Familial breast cancers (e.g., BRCA1 mutations) are frequently "triple-negative" (ER, PR, and HER2 negative) [1]. ER/PR status alone does not determine genetic predisposition. **High-Yield Clinical Pearls for NEET-PG:** * **Predictive vs. Prognostic:** ER/PR status is both. It predicts response to hormonal therapy and provides a favorable prognosis. * **HER2/neu:** This is a receptor tyrosine kinase. Overexpression (detected by IHC or FISH) indicates a poorer prognosis but predicts a good response to **Trastuzumab (Herceptin)** [2]. * **Luminal A Subtype:** These are ER+ and HER2- tumors; they have the best overall prognosis among breast cancers [1]. * **Standard of Care:** All newly diagnosed invasive breast cancers must be tested for ER, PR, and HER2 status [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1059-1060, 1064-1068. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 258-259.
Question 144: "Basal-like" carcinoma of breast can be identified as:
- A. Estrogen Receptor (ER) -ve; HER2 -ve (Correct Answer)
- B. Estrogen Receptor (ER) +ve; HER2 -ve
- C. HER2 +ve
- D. Estrogen Receptor (ER) +ve; HER2 +ve
Explanation: ### Explanation **Concept Overview:** Breast cancer is categorized into molecular subtypes based on gene expression profiling, which correlates strongly with prognosis and treatment response. **Basal-like carcinoma** is a specific molecular subtype that typically lacks the expression of hormone receptors and HER2 [1]. **Why Option A is Correct:** Basal-like carcinomas are characterized by an expression profile similar to that of normal mammary basal/myoepithelial cells (expressing cytokeratins 5/6, 14, and 17). Clinically, the vast majority (approx. 70-80%) of these tumors are **"Triple Negative,"** meaning they lack the **Estrogen Receptor (ER)**, **Progesterone Receptor (PR)**, and **HER2/neu** amplification [1], [4]. Therefore, "ER -ve; HER2 -ve" is the defining immunohistochemical feature among the choices. **Why Other Options are Incorrect:** * **Option B (ER +ve; HER2 -ve):** This profile defines the **Luminal A** (low grade) or **Luminal B** (higher grade) subtypes [3]. These are the most common types of breast cancer and have a better prognosis than basal-like tumors. * **Option C & D (HER2 +ve):** These represent the **HER2-enriched** subtype [3], [4]. These tumors overexpress the HER2/neu oncogene and are treated with targeted therapies like Trastuzumab. Basal-like tumors, by definition, do not typically overexpress HER2 [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Genetic Association:** Basal-like carcinomas are highly associated with **BRCA1 mutations**. * **Prognosis:** This subtype is aggressive, has a high histological grade, and carries a poor prognosis with a propensity for brain and lung metastasis [2]. * **Morphology:** They often show a "pushing" border and a central necrotic or fibrotic core. * **Treatment:** Since they lack ER and HER2, they do not respond to hormonal therapy (Tamoxifen) or Trastuzumab; chemotherapy is the mainstay of treatment [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1064-1066. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1066-1068. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1059-1060. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, p. 1060.
Question 145: Thymoma can be associated with all of the following conditions, EXCEPT:
- A. Superior mediastinum syndrome
- B. Myasthenia gravis
- C. Hypergammaglobulinemia (Correct Answer)
- D. Pure red cell aplasia
Explanation: **Explanation:** Thymoma is a neoplasm arising from thymic epithelial cells. It is uniquely associated with various paraneoplastic syndromes, primarily due to the thymus's role in T-cell education and immune tolerance [3]. **Why Hypergammaglobulinemia is the Correct Answer:** Thymoma is actually associated with **Hypogammaglobulinemia** (low levels of gamma globulins), a clinical triad known as **Good Syndrome**. This syndrome consists of thymoma, hypogammaglobulinemia, and cell-mediated immunodeficiency. Therefore, "Hypergammaglobulinemia" is the incorrect association and the right answer for this "EXCEPT" question. **Analysis of Incorrect Options:** * **Superior Mediastinum Syndrome:** Thymomas are the most common tumors of the **anterior** mediastinum [2]. As they grow, they can compress local structures like the Superior Vena Cava (SVC), leading to SVC syndrome (a component of superior mediastinum syndrome) [2]. * **Myasthenia Gravis (MG):** This is the most common paraneoplastic association of thymoma (seen in ~30-45% of cases). It is caused by autoantibodies against acetylcholine receptors at the neuromuscular junction [1]. * **Pure Red Cell Aplasia (PRCA):** About 5-10% of patients with thymoma develop PRCA, characterized by a selective maturation arrest of erythroid precursors in the bone marrow. **Clinical Pearls for NEET-PG:** * **Most common site:** Anterior Mediastinum [2]. * **Good Syndrome:** Thymoma + Hypogammaglobulinemia + Recurrent infections. * **Histology:** Look for "Hassall’s corpuscles" (though these are features of the normal thymus, their presence or absence helps differentiate thymic lesions) [3]. * **Staging:** The **Masaoka Staging System** is used to determine the clinical extent and prognosis of thymomas. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 213-214. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Diseases Of The Urinary And Male Genital Tracts, pp. 572-574. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 634-635.
Question 146: Which of the following is NOT a malignant feature?
- A. Aplasia (Correct Answer)
- B. Anaplasia
- C. Abnormal mitosis
- D. Pleomorphism
Explanation: ### Explanation The correct answer is **Aplasia**. To distinguish between these terms, one must understand the difference between developmental failure and cellular transformation. **1. Why Aplasia is the correct answer:** **Aplasia** refers to the failure of an organ or tissue to develop, or the cessation of regenerative replacement of cells (e.g., Aplastic Anemia) [1]. It is a **developmental or regenerative defect**, not a feature of malignancy. In aplasia, the cells are simply absent or fail to proliferate; they do not undergo the morphological transformations seen in cancer [1]. **2. Why the other options are features of malignancy:** * **Anaplasia (Option B):** This is the hallmark of malignancy [2]. It refers to a "backward formation" where cells lose their structural and functional differentiation, reverting to a primitive, undifferentiated state [3]. * **Abnormal Mitosis (Option C):** While increased mitosis can occur in benign growth, **atypical/tri-polar/quadri-polar mitotic figures** (shaped like "Mercedes-Benz" signs) are highly suggestive of malignancy, reflecting genomic instability [2]. * **Pleomorphism (Option D):** This refers to variation in the size and shape of both cells and nuclei [2]. It is a fundamental component of cellular atypia seen in malignant tumors [4]. **High-Yield Clinical Pearls for NEET-PG:** * **Anaplasia** is considered the "hallmark" of malignancy. * **N:C Ratio:** In malignant cells, the Nucleus-to-Cytoplasm ratio often increases from the normal 1:4 or 1:6 toward **1:1**. * **Hyperchromatism:** Malignant nuclei appear darker due to increased DNA content. * **Dysplasia vs. Neoplasia:** Dysplasia is disordered growth that may be reversible; once it breaches the basement membrane, it becomes invasive carcinoma [4]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 73-77. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, p. 278. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 276-278. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 278-280.
Question 147: Which of the following statements about chromothrypsis is NOT true?
- A. It is associated with chromosome rearrangements termed as chromosome shattering.
- B. It is observed in 1% to 2% of cancers as a whole.
- C. It is associated with inactivation of tumor suppressor genes and activation of oncogenes. (Correct Answer)
- D. It has an increased frequency in 25% of osteosarcomas and a high frequency in gliomas.
Explanation: **Explanation** **Chromothrypsis** (Greek for "chromosome shattering") is a localized phenomenon of genomic instability where a single or a few chromosomes undergo massive breakage and haphazard reassembly [1]. **Why Option C is the correct (NOT true) statement:** While chromothrypsis involves extensive rearrangements, its primary oncogenic driver is **not** the simultaneous inactivation of tumor suppressors and activation of oncogenes in a balanced manner. Instead, the hallmark of chromothrypsis is the **massive loss of genetic material** (deletions) and the formation of **double-minute chromosomes** (extrachromosomal DNA) that lead to high-level amplification of specific oncogenes [1]. The statement in Option C is considered "not true" in the context of standard definitions because chromothrypsis is characterized by a "one-off" catastrophic event rather than the gradual accumulation of mutations typically associated with the classic multi-step model of carcinogenesis [1]. **Analysis of other options:** * **Option A:** True. It involves dozens to hundreds of DNA breaks in a single cellular event, followed by error-prone repair (shattering and stitching) [1]. * **Option B:** True. It is estimated to occur in approximately 1% to 2% of all cancers [1]. * **Option C:** True. It shows a significantly higher prevalence in specific malignancies, notably **osteosarcomas (25%)** and **gliomas** [1]. **NEET-PG High-Yield Pearls:** * **Mechanism:** It often occurs due to the sequestration of chromosomes in **micronuclei**, which are prone to defective DNA replication and physical rupture. * **Key Feature:** It challenges the "Vogelstein model" of gradual clonal evolution; it is a **"saltatory" (leap-like)** evolution [1]. * **Clinical Significance:** Presence of chromothrypsis is generally associated with a **poor prognosis** and aggressive tumor behavior. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 326-327.
Question 148: A woman who is heterozygous for glucose-6-phosphate dehydrogenase (G6PD), a polymorphic enzyme transcribed from the X chromosome, develops chronic myeloid leukemia. Restriction fragment length polymorphism (RFLP) studies on the tumor cells for G6PD reveal that only a single form of the enzyme is transcribed. This finding supports which of the following features of neoplasia?
- A. Genetic mutation
- B. Monoclonality (Correct Answer)
- C. Mosaicism
- D. Oncogene activation
Explanation: **Explanation:** **1. Why Monoclonality is Correct:** The core concept here is the **monoclonal origin of neoplasia**. In females, one X chromosome is randomly inactivated in every cell during early embryonic development (Lyonization). Since this patient is heterozygous for G6PD, her normal tissues are a mosaic—some cells express G6PD-A and others express G6PD-B. However, if a tumor arises from a **single progenitor cell** (monoclonal), all descendant tumor cells will express the *same* X chromosome and thus the *same* G6PD isoenzyme [1]. The finding of only a single form of the enzyme in the leukemia cells confirms that the malignancy originated from the clonal expansion of one transformed cell. **2. Why Other Options are Incorrect:** * **Genetic Mutation (A):** While mutations drive neoplasia, the G6PD study specifically tracks the **lineage** of the cells rather than identifying the specific mutation that caused the leukemia (e.g., the BCR-ABL translocation). * **Mosaicism (C):** Mosaicism refers to the presence of two or more populations of cells with different genotypes in one individual (like the patient’s normal tissues). The tumor, by expressing only one enzyme, represents a **loss of mosaicism**, which is the hallmark of clonality. * **Oncogene Activation (D):** Although oncogenes (like *ABL*) are activated in CML, the G6PD isoenzyme study is a biochemical marker for cell ancestry, not a direct measure of oncogene expression. **Clinical Pearls for NEET-PG:** * **Clonality Markers:** G6PD isoenzymes were the classic method to prove clonality. Modern methods include **HUMARA** (Human Androgen Receptor Assay) and **X-linked RFLPs**. * **B-cell Clonality:** Determined by **kappa/lambda light chain ratio** (Normal is 3:1; malignancy shows a shift to 10:1 or all of one type). * **T-cell Clonality:** Determined by **T-cell receptor (TCR) gene rearrangement** studies. * **CML Hallmark:** The Philadelphia chromosome **t(9;22)** creating the **BCR-ABL** fusion gene with constitutive tyrosine kinase activity. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 224-225.
Question 149: What is the commonest site for the spread of cancers?
- A. Liver
- B. Lungs
- C. Brain
- D. Lymph Nodes (Correct Answer)
Explanation: **Explanation:** The correct answer is **Lymph Nodes**. In the natural history of most malignant tumors, **lymphatic spread** is the most common and earliest route of metastasis, particularly for carcinomas [1]. This occurs because lymphatic vessels have thinner walls and less basement membrane compared to blood vessels, making them easier for tumor cells to penetrate [1]. Once inside the lymphatics, tumor cells travel to regional nodes, which act as the first "filters" for neoplastic cells. **Analysis of Options:** * **Lymph Nodes (Correct):** Statistically the most frequent site of initial spread for the majority of cancers (especially carcinomas) [1]. * **Lungs (Incorrect):** While the lungs are the most common site for **hematogenous (blood-borne)** spread (because all venous blood flows through the pulmonary capillary bed), they are not the most common site overall. * **Liver (Incorrect):** The liver is the second most common site for hematogenous spread and the most common site for cancers originating in the portal drainage area (e.g., GI tract). * **Brain (Incorrect):** Though a significant site for certain cancers (like Lung or Breast), it is far less common than lymphatic or pulmonary involvement. **High-Yield Clinical Pearls for NEET-PG:** * **Carcinomas** typically spread via **lymphatics** (Exception: Renal Cell Carcinoma and Hepatocellular Carcinoma spread via veins). * **Sarcomas** typically spread via the **hematogenous** route. * **Sentinel Lymph Node:** The first node in a regional lymphatic basin that receives lymph flow from a primary tumor; its biopsy is crucial for staging (e.g., in Breast Cancer and Melanoma). * **Virchow’s Node:** An enlarged left supraclavicular node, often the first sign of an occult abdominal malignancy (Troisier sign). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 233-235.
Question 150: What is the most specific immunohistochemical marker for melanoma cells?
- A. S-100
- B. Melan-A
- C. HMB-45 (Correct Answer)
- D. Chromogranin
Explanation: ### Explanation **Correct Answer: C. HMB-45** **Why HMB-45 is the correct answer:** HMB-45 (Human Melanoma Black-45) is a monoclonal antibody that reacts against **gp100**, a glycoprotein found in premelanosomes. It is considered the **most specific** marker for melanoma because it is absent in most non-melanocytic tumors and normal adult melanocytes (except fetal/activated ones) [1]. While its sensitivity is lower than S-100, its high specificity makes it the gold standard for confirming a melanocytic origin in a poorly differentiated tumor. **Analysis of Incorrect Options:** * **A. S-100:** This is the **most sensitive** marker for melanoma. However, it is **not specific** as it is also expressed in cells of neural crest origin, including Schwann cells, glial cells, chondrocytes, and Langerhans cells. * **B. Melan-A (MART-1):** This is a very useful marker for melanocytic differentiation. While highly sensitive and more specific than S-100, HMB-45 remains the classic textbook answer for "most specific" due to its lack of staining in resting normal melanocytes. * **D. Chromogranin:** This is a marker for **neuroendocrine tumors** (e.g., carcinoid, small cell carcinoma) and has no role in the diagnosis of melanoma. **High-Yield Clinical Pearls for NEET-PG:** * **Most Sensitive Marker:** S-100 (Best for screening/ruling out). * **Most Specific Marker:** HMB-45 (Best for ruling in) [1]. * **Newer Highly Specific Marker:** **SOX10** is gaining prominence in recent literature as both highly sensitive and specific for melanoma and spindle cell variants. * **Vimentin:** Melanomas are almost always Vimentin positive (mesenchymal origin marker). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, pp. 1151-1152.
Practice by Chapter
Nomenclature and Classification of Tumors
Practice Questions
Characteristics of Benign and Malignant Neoplasms
Practice Questions
Molecular Basis of Cancer
Practice Questions
Carcinogenesis and Carcinogens
Practice Questions
Tumor Progression and Metastasis
Practice Questions
Tumor Markers
Practice Questions
Paraneoplastic Syndromes
Practice Questions
Genetic Basis of Cancer
Practice Questions
Tumor Immunity
Practice Questions
Cancer Epidemiology and Prevention
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free